Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 16/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16413956 | 0.93 | FGFR1 (0.59) | FGFR1FGFR3 | |
| SCHEMBL15211542 | 0.92 | FGFR1 (0.61) | FGFR1FGFR3 | |
| SCHEMBL15217993 | 0.92 | FGFR1 (0.61) | FGFR1FGFR3 | |
| SCHEMBL15212919 | 0.92 | FGFR1 (0.58) | FGFR1FGFR3 | |
| SCHEMBL15217902 | 0.92 | FGFR1 (0.59) | FGFR1FGFR3 | |
| Hydrochloric Acid SCHEMBL15211653 | 0.91 | FGFR1 (0.58) | FGFR1FGFR3 | |
| SCHEMBL15217995 | 0.89 | FGFR1 (0.58) | FGFR1FGFR3 | |
| SCHEMBL15217990 | 0.89 | FGFR1 (0.58) | FGFR1FGFR3 | |
| SCHEMBL15217811 | 0.89 | FGFR1 (0.58) | FGFR1FGFR3 | |
| SCHEMBL15217983 | 0.89 | FGFR1 (0.71) | FGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475815-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLETUAL PROPERTY GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| US-9475815-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLETUAL PROPERTY GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| US-9475815-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLETUAL PROPERTY GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-2817311-B1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2817311-B1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| EP-2817311-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013124316-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013124316-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | STK25, JAK2, PTK2B | FGFR1 186/4885FGFR3 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.